Status:
COMPLETED
Allogeneic Transplantation From Related Haploidentical Donors
Lead Sponsor:
Stanford University
Conditions:
Blood Cancer
Leukemia
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total...
Detailed Description
An alternative to conventional allogeneic bone marrow transplantation is by using a non-myeloablative conditioning regimen. This regime would consist of both; total lymphoid irradiation (TLI) and anti...
Eligibility Criteria
Inclusion
- Age ≥ 50 years with hematologic malignancies treatable by a mixed chimera allogeneic HCT.
- For patients ≤ 50 years of age with hematologic malignacies treatable with mixed chimera HCT who because of pre-exisiting medical conditions or prior therapy are considered to be at high risk for regimen-related toxicity associated with conventional transplants.
- Indolent advanced stage NHL, CLL, HD - Must have received and failed front-line therapy.
- Multiple myeloma (Stage II or III) - Must have received prior chemotherapy. Consolidation after prior autografting is permitted.
- AML/ALL - Must be in complete hematologic remission and have received cytotoxic chemotherapy at some stage before transplant. Patients with molecular or cytogenetic relapse will be accepted providing a donor is available. Patients with persistent or refractory disease will be considered on a case by case basis and transplants must be approved by the principal investigator.
- CML - Patients will be accepted in chronic or accelerated phase. Patients who have received prior autografts after high dose therapy or have undergone intensive chemotherapy for either peripheral blood stem cell mobilization or treatment of advanced CML may be enrolled provided they are in CR, chronic phase or accelerated phase.
- MDS - All patients with MDS will be eligible for this protocol, however, those patients with \>10% blasts will require chemotherapy to reduce the blast % to \< 10%.
- SAA - Patients with severe aplastic anemia who have failed front line therapy.
- A fully HLA-identical sibling donor is not available.
- A matched unrelated donor has not been identified.
- A haploidentical related donor is available who is in good health and does not have contraindications to donation.
Exclusion
- Patients with rapidly progressive intermediate or high grade NHL
- Uncontrolled CNS involvement with disease
- Fertile men
- Women unwilling to use contraceptive techniques during and for 12 months following treatment
- Females who are pregnant
- Cardiac function: ejection fraction \< 30% or cardiac failure requiring therapy
- Pulmonary: DLCO \< 40% predicted and/or receiving supplementary continuous oxygen
- Liver function abnormalities: elevation of bilirubin to \> 4 mg/dl and/or transaminases \> 3x the upper limit of normal. If hyperbilirubinemai is due to a known cause that will not increase the risks of transplant, than this upper limit may be exceeded.
- Renal: creatinine clearance \< 50 cc/min (24 hour urine collection)
- Karnofsky performance score \< 60%
- Patients with poorly controlled hypertension.
- Documented fungal disease that persists despite treatment
- HIV positive patients.
- Hepatitis B and C positive patients will be evaluated on a case by case basis
- Psychiatric disorders or psychosocial problems which in the opinion of the primary physician or principal investigator would place the patient at unacceptable risk from this regimen.
Key Trial Info
Start Date :
August 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00185692
Start Date
August 1 2000
End Date
December 1 2010
Last Update
December 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305